Joseph S. Cavanaugh - Concepedia

Author

Joseph S. Cavanaugh

Centers for Disease Control and Prevention ORCID

Also Known As

J Sean Cavanaugh, J. Cavanaugh, J. S. Cavanaugh, J. Sean Cavanaugh, Joseph Cavanaugh, Joseph S Cavanaugh, Joseph S. Cavanaugh, Joseph Sean Cavanaugh

Publications

810

Citations

H-Index

Concepts

All Affiliations

Centers for Disease Control and Prevention Epidemic Intelligence Service AIDS United Centers for Disease Control and Prevention Kenya Medical Research Institute

About

Joseph S. Cavanaugh is an author at Centers for Disease Control and Prevention specializing in medicine, tuberculosis, and tuberculosis prevention.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	215
2	Epidemiology	3	3	153
3	Health Sciences	2	2	108
4	Public Health	2	2	88
5	Microbiology	1	1	65

Joseph S. Cavanaugh

Publications

694

Citations

H-Index

Page 1

	Year	Citations
TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings Ishani Pathmanathan, Sevim Ahmedov, Eric Pevzner, The International Journal of Tuberculosis and Lung Disease Tuberculosis PreventionDrug ResistancePreventive MedicineTb Preventive TherapyGlobal Tb Epidemic	2018	78
Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis [Short communication] Sarah E. Smith, Ekaterina V. Kurbatova, Joseph S. Cavanaugh, The International Journal of Tuberculosis and Lung Disease World Health OrganizationPulmonary TuberculosisHealth SciencesAntibioticsTuberculosis Prevention	2011	65
Epidemiology of Pyrazinamide-Resistant Tuberculosis in the United States, 1999–2009 Ekaterina V. Kurbatova, Joseph S. Cavanaugh, Tracy Dalton, Clinical Infectious Diseases	2013	65
Human Tuberculosis Caused by<i>Mycobacterium bovis</i>in the United States, 2006–2013 Colleen Scott, Joseph S. Cavanaugh, Robert Pratt, Clinical Infectious Diseases	2016	53
Rifampicin-resistant <I>Mycobacterium tuberculosis</I>: susceptibility to isoniazid and other anti-tuberculosis drugs [Short communication] Ekaterina V. Kurbatova, Joseph S. Cavanaugh, N. Sarita Shah, The International Journal of Tuberculosis and Lung Disease Tuberculosis PreventionPharmacotherapyAntimicrobial ChemotherapyAntibiotic ResistanceDrug Resistance	2012	43
Performance of Clinical Screening Algorithms for Tuberculosis Intensified Case Finding among People Living with HIV in Western Kenya Surbhi Modi, Joseph S. Cavanaugh, Ray W. Shiraishi, PLoS ONE	2016	38
Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002–2005 Joseph S. Cavanaugh, Boris Y. Kazennyy, Minh Ly Nguyen, The International Journal of Tuberculosis and Lung Disease	2012	33
Epidemiology of smear-negative pulmonary tuberculosis in the United States, 1993–2008 Neha Shah, Joseph S. Cavanaugh, Robert Pratt, The International Journal of Tuberculosis and Lung Disease	2012	33
Policies, practices and barriers to implementing tuberculosis preventive treatment—35 countries, 2017 Diya Surie, Julia D. Interrante, Ishani Pathmanathan, The International Journal of Tuberculosis and Lung Disease	2019	29
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters Joseph S. Cavanaugh, Ruwen Jou, Mei-Hua Wu, Journal of Antimicrobial Chemotherapy	2017	28

Page 1